Survival benefit of concurrent chemoradiotherapy for advanced ampulla of Vater cancer

• Published in: World journal of clinical cases 2024-01, Vol.12 (2), p.267-275
• Main Authors: Kwon, Chae Hwa, Seo, Hyung Il, Kim, Dong Uk, Han, Sung Yong, Kim, Suk, Lee, Nam Kyung, Hong, Seung Baek, Ahn, Ji Hyun, Park, Young Mok, Noh, Byeong Gwan
• Format: Article
• Language: English
• ISSN: 2307-8960; 2307-8960
• DOI: 10.12998/wjcc.v12.i2.267

Currently, there is no standard adjuvant therapy for patients with resected ampulla of Vater (AoV) cancer. To evaluate the effectiveness of adjuvant concurrent chemoradiotherapy (CCRT) in patients with advanced AoV cancer who underwent curative resection. This single-centered, retrospective study included 29 patients with advanced AoV cancer who underwent pancreaticoduodenectomy between 2006 and 2018. The impact of CCRT on advanced AoV cancer was analyzed. The 1-, 3-, and 5-yr recurrence-free survival (RFS) rates for patients with advanced AoV cancer were 82.8%, 48.3%, and 40.8%, respectively, and the overall survival (OS) rates were 89.7%, 62.1%, and 51.7%, respectively. Lymphovascular invasion was found to be a significant risk factor for RFS and OS in patients with advanced AoV cancer in the univariate analysis, whereas T stage and lymph node metastasis were significantly associated with OS in the multivariate analysis. Compared to the patients who did not receive adjuvant CCRT, those who received adjuvant CCRT did not show statistically significant improvements in the RFS and OS, although they had a significantly lower average age and significantly higher platelet-to-lymphocyte ratio. Adjuvant CCRT did not improve survival outcomes in patients with advanced AoV cancer. These findings contribute to existing knowledge on the effectiveness of CCRT in this patient population and provide important insights for clinical decision-making.